Figure 3

Pathologic levels of biomarkers in different age groups. (A-D) Shares of subjects with presumed pathologic levels of the CSF biomarkers Aβ42, T-tau, P-tau, and Aβ42/P-tau-ratio, in that order. For NFL (E), we defined a cut-off by using an independent dataset on 108 CSF samples from clinically examined neurologically healthy adults (age median, 38 years; range, 18 to 76 years). For the AD biomarkers (F), we used cut-offs previously generated at our laboratory, in a study with long follow-up time of early-stage AD patients.